Skip to main content
SpringerLink
Log in

Role of lipoprotein-associated phospholipase A2 in atherosclerosis

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a biomarker that can be used to assess the risk for cardiovascular disease and events. In addition to being a useful marker of a risk factor, several studies suggest that Lp-PLA2 has a pathophysiologic role in the atherosclerotic disease process. In this article, we review this aspect and its therapeutic implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143.

    Article  PubMed  CAS  Google Scholar 

  2. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  3. Albert CM, Ma J, Rifai N, et al.: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002, 105:2595–2599.

    Article  PubMed  CAS  Google Scholar 

  4. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868–874.

    Article  PubMed  CAS  Google Scholar 

  5. Oei H-HS, van der Meer IM, Hofman A, et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570–575.

    Article  PubMed  CAS  Google Scholar 

  6. Vasan RS, Sullivan LM, Roubenoff R, et al.: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486–1491.

    Article  PubMed  CAS  Google Scholar 

  7. Hurt-Camejo E, Camejo G, Peilot H, et al.: Phospholipase A2 in vascular disease. Circ Res 2001, 89:298–304.

    Article  PubMed  CAS  Google Scholar 

  8. Hakkinen T, Luoma JS, Hiltunen MO, et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999, 19:2909–2917.

    PubMed  CAS  Google Scholar 

  9. Tsimikas S, Willerson JT, Ridker PM: C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47:C19–C31.

    Article  PubMed  CAS  Google Scholar 

  10. Brilakis ES, McConnell JP, Lennon RJ, et al.: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005, 26:137–144.

    Article  PubMed  CAS  Google Scholar 

  11. Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923–931.

    Article  PubMed  CAS  Google Scholar 

  12. Arakawa H, Qian JY, Baatar D, et al.: Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 2005, 111:3302–3309.

    Article  PubMed  CAS  Google Scholar 

  13. Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003, 14:347–352.

    Article  PubMed  CAS  Google Scholar 

  14. Marathe GK, Zimmerman GA, McIntyre TM: Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2003, 278:3937–3947.

    Article  PubMed  CAS  Google Scholar 

  15. McConnell JP, Hoefner DM: Lipoprotein-associated phospholipase A2. Clin Lab Med 2006, 26:679–697.

    Article  PubMed  Google Scholar 

  16. Morgan EN, Boyle EM Jr, Yun W, et al.: Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999, 100:365II–368II.

    Google Scholar 

  17. Iribarren C: Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions. Arterioscler Thromb Vasc Biol 2006, 26:5–6.

    Article  PubMed  CAS  Google Scholar 

  18. Maier W, Altwegg LA, Corti R, et al.: Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005, 111:1355–1361.

    Article  PubMed  CAS  Google Scholar 

  19. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 1988, 85:2805–2809.

    Article  PubMed  CAS  Google Scholar 

  20. Lavi S, Lavi R, McConnell JP, et al.: Lipoprotein-associated phospholipase A(2): review of its role as a marker and a potential participant in coronary endothelial dysfunction. Mol Diagn Ther 2007, 11:219–226.

    PubMed  CAS  Google Scholar 

  21. Suwaidi JA, Hamasaki S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948–954.

    PubMed  CAS  Google Scholar 

  22. Yang EH, McConnell JP, Lennon RJ, et al.: Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006, 26:106–111.

    Article  PubMed  CAS  Google Scholar 

  23. Lavi S, McConnell JP, Rihal CS, et al.: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715–2721.

    Article  PubMed  CAS  Google Scholar 

  24. Kolodgie FD, Burke AP, Skorija KS, et al.: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523–2529.

    Article  PubMed  CAS  Google Scholar 

  25. Mannheim D, Herrmann J, Versari D, et al.: Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaque. Stroke 2008, In press.

  26. Gazi I, Lourida ES, Filippatos T, et al.: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264–2273.

    Article  PubMed  CAS  Google Scholar 

  27. Blencowe C, Hermetter A, Kostner GM, Deigner HP: Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995, 270:31151–31157.

    Article  PubMed  CAS  Google Scholar 

  28. Kiechl S, Willeit J, Mayr M, et al.: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2007, 27:1788–1795.

    Article  PubMed  CAS  Google Scholar 

  29. Tsimikas S, Tsironis LD, Tselepis AD: New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2094–2099.

    Article  PubMed  CAS  Google Scholar 

  30. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837–842.

    Article  PubMed  CAS  Google Scholar 

  31. Koenig W, Khuseyinova N, Lowel H, et al.: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004, 110:1903–1908.

    Article  PubMed  CAS  Google Scholar 

  32. Packard CJ, O’Reilly DS, Caslake MJ, et al.: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000, 343:1148–1155.

    Article  PubMed  CAS  Google Scholar 

  33. Blake GJ, Dada N, Fox JC, et al.: A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001, 38:1302–1306.

    Article  PubMed  CAS  Google Scholar 

  34. Sabatine MS, Morrow DA, O’Donoghue M, et al.: Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2463–2469.

    Article  PubMed  CAS  Google Scholar 

  35. O’Donoghue M, Morrow DA, Sabatine MS, et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation 2006, 113:1745–1752.

    Article  PubMed  CAS  Google Scholar 

  36. Gerber Y, McConnell JP, Jaffe AS, et al.: Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006, 26:2517–2522.

    Article  PubMed  CAS  Google Scholar 

  37. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity c-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2005, 165:2479–2484.

    Article  PubMed  CAS  Google Scholar 

  38. Elkind MS, Tai W, Coates K, et al.: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073–2080.

    Article  PubMed  CAS  Google Scholar 

  39. Garza CA, Montori VM, McConnell JP, et al.: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159–165.

    Article  PubMed  CAS  Google Scholar 

  40. Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006, 26:1586–1593.

    Article  PubMed  CAS  Google Scholar 

  41. Iribarren C, Gross MD, Darbinian JA, et al.: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005, 25:216–221.

    PubMed  CAS  Google Scholar 

  42. Saougos VG, Tambaki AP, Kalogirou M, et al.: Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007, 27:2236–2243.

    Article  PubMed  CAS  Google Scholar 

  43. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  44. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 2004, 292:1307–1316.

    Article  PubMed  Google Scholar 

  45. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  46. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898–904.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, Mayo Clinic, Mary Brigh 4-523, 200 First Street SW, Rochester, MN, 55905, USA

    Amir Lerman

Authors
  1. Shahar Lavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joerg Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronit Lavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph P. McConnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lilach O. Lerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amir Lerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Lerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lavi, S., Herrmann, J., Lavi, R. et al. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep 10, 230–235 (2008). https://doi.org/10.1007/s11883-008-0036-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0036-9

Keywords

Search

Navigation